The Sunshine Act: What it means to you, what you need to do

Article

The Physician Payments Sunshine Act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to members of the health care community.

 

Washington-Before the fiscal year goes any farther, this may be a good time to review the newly implemented Physician Payments Sunshine Act, better known simply as the Sunshine Act, which went into effect August 1.

The Sunshine Act is meant to enhance transparency in relationships between the pharmaceutical and drug manufacturing industry and doctors or teaching hospitals. The act requires manufacturers of drugs, medical devices, and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to members of the health care community.

Manufacturers are required to collect and track payment, transfer, and ownership information. The compiled data is then submitted to the Centers for Medicare & Medicaid Services (CMS) on an annual basis. Also, manufacturers and group purchasing organizations must report certain ownership interests held by doctors and their immediate family members.

Most of the information contained in the reports will be available on a public, searchable Web site starting Q4 2014. Doctors have the right to review their reports and challenge data that are false, inaccurate, or misleading.

To help doctors and the medical community at large navigate this new reporting obligation, the AMA offers a Toolkit for Physician Financial Transparency Reports . The Toolkit is a guide to complying with the process before your 2013 financial data is published online next year.

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.